Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Holdings Reduced by Yousif Capital Management LLC

Yousif Capital Management LLC lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,251 shares of the specialty pharmaceutical company’s stock after selling 716 shares during the period. Yousif Capital Management LLC owned 0.06% of Collegium Pharmaceutical worth $562,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Pacer Advisors Inc. increased its position in Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after acquiring an additional 883,380 shares during the period. Invesco Ltd. raised its stake in shares of Collegium Pharmaceutical by 1.7% during the third quarter. Invesco Ltd. now owns 1,159,604 shares of the specialty pharmaceutical company’s stock valued at $25,917,000 after purchasing an additional 19,740 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Collegium Pharmaceutical by 178.1% in the third quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock worth $9,513,000 after purchasing an additional 272,565 shares during the period. Charles Schwab Investment Management Inc. grew its position in Collegium Pharmaceutical by 5.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 310,139 shares of the specialty pharmaceutical company’s stock valued at $6,932,000 after buying an additional 14,667 shares in the last quarter. Finally, Loomis Sayles & Co. L P increased its stake in Collegium Pharmaceutical by 32.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock valued at $6,116,000 after buying an additional 67,439 shares during the period.

Collegium Pharmaceutical Stock Performance

COLL opened at $37.51 on Monday. The business has a fifty day simple moving average of $37.56 and a 200-day simple moving average of $31.91. The firm has a market cap of $1.23 billion, a PE ratio of 31.79 and a beta of 1.06. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The business had revenue of $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. As a group, equities analysts predict that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on COLL. Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 price target on shares of Collegium Pharmaceutical in a research note on Thursday, April 11th. Truist Financial increased their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $39.00 target price (up previously from $37.00) on shares of Collegium Pharmaceutical in a research note on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.